Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with Tislelizumab and Chemotherapy in Urothelial Carcinoma
NCT06364904Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trilaciclib in urothelial carcinoma (UC) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Progression-Free Survival at 24 months and Incidence of Grade 3/4 Neutropenia at 28 days. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06364904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364904.